hackint0sh/New-Dataset huggingface dataset:
The primary aim is to investigate the impact of exercise on V02peak. Secondarily endpoints aim to investigate changes in physical function, patient related outcomes and cardiac function before and after exercise. conditions: Advanced Lung Carcinoma conditions: First Line Treatment conditions: Second Line Treatment conditions: NSCLC Stage IV conditions: NSCLC Stage IIIB conditions: Palliative Treatment conditions: NSCLC Stage IIIC studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: BREATH is a prospective 3-arm 2:1:1 randomized controlled trial (RCT). The first arm represents the control group, which will receive the standard treatment for the first 12 weeks (recommendations for physical activity during cancer treatment). The other two arms represent the exercise groups, one group will receive individualized endurance training and the other group a combination of individualized endurance and strength training. All arms will be treated for 12 weeks. Afterwards, the patients in the control group are randomized to one of the other two study arms and then also treated twice for 12 weeks. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 104 type: ESTIMATED name: Exercise intervention measure: Maximum oxygen uptake (VO2 peak [ml/min/kg]) measure: Functional Assessment of Chronic Illness Therapy - Fatigue (FACT-F) measure: European Organisation for Research and Treatment of Cancer (EORTC QLQ C30) measure: European Organisation for Research and Treatment of Cancer Lung cancer module (EORTC-LC13) measure: Arterial blood pressure measure: Change in ECG measure: Adherence to exercise intervention measure: Drop-out rate measure: Recruitment rate measure: Serious Adverse Event/Adverse Events measure: Therapy response measure: Treatment Toxicity measure: Treatment scheme measure: NT-pro-BNP measure: High sensitive troponin I measure: Erythrocytes measure: Hemoglobin measure: Leukocytes measure: Lymphocytes measure: Neutrophils measure: CRP measure: CYRFRA 21-1 measure: Physical function (Hypothetical One-repetition maximum) measure: Blood gas analysis pH value measure: Blood gas analysis (PAO2) measure: Blood gas analysis (SaO2) measure: Blood gas analysis (PCO2) measure: Blood gas analysis (BE) measure: Blood gas analysis (HCO3) measure: Blood gas analysis (SBCe) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West German Cancer Center (Department of Palliative medicine and Department of Medical Oncology), University Hospital Essen city: Essen state: North Rhine-Westphalia zip: 45147 country: Germany name: Mitra Tewes, PD. Dr. role: CONTACT email: mitra.tewes@uk-essen.de name: Nico De Lazzari, M. Sc. role: CONTACT phone: +49 201 723-82035 email: nico.delazzari@uk-essen.de name: Mitra Tewes, PD. Dr. role: PRINCIPAL_INVESTIGATOR name: Marcel Wiesweg, PD. Dr. role: SUB_INVESTIGATOR name: Miriam Götte, PD. Dr. role: SUB_INVESTIGATOR name: Eva-Maria Hüßler, Dr. role: SUB_INVESTIGATOR name: Andreas Stang, Prof. Dr. role: SUB_INVESTIGATOR name: Matthias Totzeck, Prof. Dr. role: SUB_INVESTIGATOR lat: 51.45657 lon: 7.01228 hasResults: False
nctId: NCT06374147 id: STUDY00004467 briefTitle: "Prapela® SVS Incubator Pad for Apnea of Prematurity acronym: Prapela AOP overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2026-06-01 date: 2026-12-31 date: 2024-04-18 date: 2024-04-18 name: Tufts Medical Center class: OTHER name: University of Alabama at Birmingham briefSummary: The study proposes to complete the development of and then establish the safety, efficacy, and clinical risk/benefit of a novel hospital incubator pad with stochastic vibrotactile stimulation (SVS) that will provide a complementary treatment and the first improvement in the clinical management of apnea of prematurity (AOP) in over 20 years. Currently, the only approved therapy for AOP is Caffeine Citrate. The SVS mattress pad can prove to be an effective, non-invasive adjunct to Caffeine Citrate for preterm infants with potential to shorten the need for respiratory support as well as overall shortened length of stay. conditions: Apnea of Prematurity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: SVS mattress measure: Reduce apnea events by 30% or more in the three days after study entry measure: Reduce the number of days caffeine citrate is used after study entry by 3 days or more measure: Reduce the number of days of respiratory support by 3 days or more sex: ALL minimumAge: 0 Days maximumAge: 3 Months stdAges: CHILD hasResults: False
nctId: NCT06374134 id: STUDY00004835 briefTitle: The Impact of Community and Patient Engagement Practices on Vaccine Confidence in the United States overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-11 date: 2025-02 date: 2024-04-18 date: 2024-04-18 name: Tufts University class: OTHER name: Merck Sharp & Dohme LLC briefSummary: The primary objective of this study is to demonstrate an empirical relationship between community- engagement practices, and between patient-centric clinical trial design, execution and communication practices, and vaccine adoption experience.
Our hypothesis is that patient-centric clinical trial activity, and community engagement in late-stage clinical trials and early-stage commercialization, reduces vaccine hesitancy and increases vaccine confidence among health care providers overall and within diverse patient communities and ultimately drives faster vaccine adoption. conditions: Vaccine Hesitancy studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: RETROSPECTIVE count: 30 type: ESTIMATED name: Community Engagement Practice name: Patient-Centric Protocol Element measure: Units of Vaccine Dispensed sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06374121 id: POWER briefTitle: Kidney Perfusion With or Without Absorption acronym: POWER overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-06 date: 2024-04-18 date: 2024-04-18 name: Mario Negri Institute for Pharmacological Research class: OTHER briefSummary: In this single-center, pilot, prospective, randomized study, the investigators will compare the biochemical profiles of the perfusate and the functional parameters of five kidneys perfused with Integrated PerLife® system and "PerSorb ECOS-300CY ™" sorbent (adsorption groups) with the profiles of the perfusate and functional parameters of five matched kidneys perfused with Integrated PerLife® system only (non-adsorption group). Kidneys from marginal donors with a clinical indication to pre-transplant histological evaluation (donor \>70-years-old or aged 60 to 69 years but with hypertension, diabetes and/or clinical proteinuria) will be allocated to perfusion with or without adsorption using a 1:1 randomization ratio. When both donor kidneys will have a score from 0 to 4, the two kidneys will be used for two single transplants. When one kidney will have a score from 0 to 4 and the other kidney will have a score of 5 or more, and when both kidneys will have a score from 5 to 7, the two kidneys will be transplanted together into the same recipient. If one kidney will have a score from 5 to 7 and the other kidney will have a score of 8 or greater, the two kidneys will be discarded. With the use of the minimization method, the randomization will be planned in order to have the same number of single or dual transplants in the perfusion kidney groups with or without adsorption. Donor selection, kidney evaluation and allocation and recipient management will be based on per center practice. conditions: Kidney Replacement studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: To compare the biochemical profiles of the perfusate obtained from 5 kidneys treated with perfusion and concomitant adsorption, with that of the perfusate obtained from 5 kidneys treated with perfusion without adsorption. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: PerSorb cartridge (CytoSorbents Europe GmbH, Germany) name: PerLife PerKidney measure: Oxidative stress markers measure: Acute kidney injury markers measure: Inflammatory cytokine markers measure: Complement activation markers measure: Vascular resistances measure: Perfusate sample collection sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò city: Bergamo state: BG zip: 24027 country: Italy lat: 45.69601 lon: 9.66721 hasResults: False
nctId: NCT06374108 id: Neuro_Exercise briefTitle: Resistance Training and Corticospinal Excitability in Multiple Sclerosis acronym: NEXIMS overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-05-31 date: 2024-04-18 date: 2024-04-29 name: University of Aarhus class: OTHER name: Aarhus University Hospital name: University of Copenhagen briefSummary: The goal of the present study is to investigate effects of progressive resistance training on central nervous system functioning (corticospinal excitability (CSE)) and walking capacity in persons with multiple sclerosis (pwMS). A total of 54 pwMS will be enrolled and randomized into 1 of 3 groups: high dose resistant training (RT), low dose RT, and waitlist control. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Progressive resistance training measure: MEP/Mmax ratio measure: Muscle strength measure: Voluntary activation I measure: Voluntary activation II measure: Force Steadiness measure: Rate of Force Developement measure: Ultrasound measure: Resting Motor Threshold (rMT) measure: Active Motor Threshold (aMT) measure: MEP latency (resting) measure: MEP latency (active) measure: MEP amplitude (resting) measure: MEP amplitude (active) measure: Short-interval intracortical Inhibition (SICI) measure: Intracortical facilitation (ICF) measure: Cortical Silent Period (CSP) measure: Central Motor Conduction Time (CMCT) measure: EEG-EMG coherence (0-1) measure: Timed 25 feet walk test (T25FWT) measure: 6-minute walk test (6MWT) measure: Six spot step test (SSST) measure: 5 sit-to-stand (5STS) measure: 9-step stair ascend (9SSA) measure: Patient determined disease steps (PDDS) measure: Multiple Sclerosis Walking Scale (MSWS) measure: Modified fatigue impact scale (MFIS) measure: MS impact scale (MSIS) measure: Falls-efficacy scale - international (FES-1) measure: The Physical Activity Enjoyment Scale (PACES) measure: Brief pain inventory (BPI) measure: Baecke physical activity measure: Accelerometry sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06374095 id: ONSET briefTitle: 1 vs 7 RATG Infusions in Renal Transplantation acronym: ONSET overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2025-06 date: 2024-04-18 date: 2024-04-18 name: Mario Negri Institute for Pharmacological Research class: OTHER briefSummary: This trial is to compare the risk/benefit profile over six-month follow-up of two induction immunosuppressive regimens based on one or seven low-dose perioperative RATG infusions on top of the same induction therapy with basiliximab and steroid (progressively tapered post-transplant) and maintenance therapy with calcineurin inhibitors and mycophenolate mofetil/mycophenolic acid in 75 recipients (25 Patients and 50 Reference-Patients) of a single or dual first kidney transplant from an ideal or marginal donor at a single Renal Transplant Center. conditions: Kidney Replacement studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 75 type: ESTIMATED name: RATG name: Basiliximab measure: Incidence of thrombocytopenia and/or leukopenia measure: Occurrence of anemia measure: Occurrence of viral infections measure: Occurrence of pneumonia measure: Occurrence of opportunistic infections measure: Occurrence of delayed graft function measure: Occurrence of allograft rejection measure: Occurrence of biopsy proven rejection measure: Survival measure: Platelet and WBC counts measure: Creatinine levels measure: Adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ASST HPG23 - Unità di Nefrologia city: Bergamo state: BG zip: 24127 country: Italy lat: 45.69601 lon: 9.66721 hasResults: False
nctId: NCT06374082 id: HKWC-2024-179 briefTitle: Instant Messaging Reinforcement for Smoking Cessation Counseling Training overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-08 date: 2024-10 date: 2024-04-18 date: 2024-04-18 name: The University of Hong Kong class: OTHER briefSummary: This research aims to assess the impact of instant messaging reinforcement on the learning outcomes of smoking cessation counseling (SCC) training among master of nursing (MN) students at the University of Hong Kong. The hypotheses suggest that this reinforcement can enhance students' SCC knowledge and techniques, improve their perception of SCC, and increase their application of SCC in clinical work.
Data analysis will be performed in Statistical Package for the Social Sciences (SPSS), using descriptive statistics, intention-to-treat analysis, Chi-square and t-tests, Cohen's d for effect size, and linear mixed models. The expected results suggest that instant messaging reinforcement will enhance SCC knowledge, attitude, and practice among MN students. conditions: Smoking Cessation Counseling Ability conditions: Smoking Cessation Counseling Practice studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE maskingDescription: Double-blinding technique will be used to conceal the allocation. Participants will not know which group they are in as placebo messages will be introduced. Using a central allocation web-based-controlled randomization, outcome assessors and data analysts will be blind to group allocation, only the principal investigator will be aware of who belongs to the control and intervention groups. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: WhatsApp message measure: SCC practice measurement measure: SCC knowledge score measure: SCC attitude score measure: SCC practice score sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Hong KongLKS Faculty of Medicine city: Hong Kong zip: 00 country: Hong Kong name: Derek Yee Tak Cheung, PhD role: CONTACT phone: +852 3917 6652 email: derekcheung@hku.hk name: Derek Yee Tak Cheung, PhD role: PRINCIPAL_INVESTIGATOR name: Xiaoyun Xie, PhDcandidate role: SUB_INVESTIGATOR name: Guowen Zhang, DN student role: SUB_INVESTIGATOR name: Tzu Tsun Luk, PhD role: SUB_INVESTIGATOR name: Man Ping Wang, PhD role: SUB_INVESTIGATOR name: Siu Chee Chan, PhD role: SUB_INVESTIGATOR lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06374069 id: NL81887.058.23 briefTitle: Longevity Families of the Netherlands acronym: LOF-NL overallStatus: RECRUITING date: 2023-09-11 date: 2026-12 date: 2026-12 date: 2024-04-18 date: 2024-04-18 name: Leiden University Medical Center class: OTHER name: Jacobijn Gussekloo, Prof. dr. name: Simon P. Mooijaart, Prof. dr. briefSummary: The demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Families surviving into exceptionally high ages (longevity) in good physical and mental health illustrate that this is physiologically possible. Such families harbor cross generational socio-genetic mechanisms that mediate healthy aging and protection from (multi)morbidity.
The purpose of our research is: to identify gene variants associated with healthy aging and protection from (multi)morbidity; to study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component. conditions: Longevity conditions: Familial Longevity conditions: Extreme Longevity conditions: Aging studyType: OBSERVATIONAL observationalModel: FAMILY_BASED timePerspective: CROSS_SECTIONAL count: 600 type: ESTIMATED measure: Identifying the genetic variants of Familial Longevity measure: Studying the environmental factor of Familial Longevity through questionnaires and its interaction with the genetic component sex: ALL minimumAge: 75 Years stdAges: OLDER_ADULT facility: Leiden University Medical Center status: RECRUITING city: Leiden state: South Holland zip: 2333ZA country: Netherlands lat: 52.15833 lon: 4.49306 hasResults: False
nctId: NCT06374056 id: 0458 briefTitle: Kintsugi Voice Device Pilot Study overallStatus: RECRUITING date: 2024-03-22 date: 2025-03-22 date: 2025-07-22 date: 2024-04-18 date: 2024-04-19 name: Kintsugi Mindful Wellness, Inc. class: INDUSTRY name: Sonar Strategies name: Vituity Psychiatry briefSummary: A prospective, single arm, non-randomized, pilot clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made by a clinician using the Structured Clinical Interview for DSM-5 (SCID-5-CT) for up to 500 English speaking adult patients ages 22 and older living in the United States. Recruitment will occur for 1 year and participation will be for up to 2 weeks. conditions: Depression conditions: Depression Moderate conditions: Depression Severe conditions: Depression Mild studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Kintsugi Voice Device measure: Sensitivity and Specificity of Kintsugi Voice Device Relative to the SCID-5 measure: PPV, NPV, AUC, F-Score of Kintsugi Voice Device Relative to the SCID-5 measure: Sensitivity, Specificity, PPV, NPV, AUC, F-Score of Kintsugi Voice Device Relative to the Severity of the SCID-5-CT measure: Sensitivity, Specificity, PPV, NPV, AUC, F-Score of Kintsugi Voice Device Relative to the PHQ-9 sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kintsugi Mindful Wellness Inc. status: RECRUITING city: Berkeley state: California zip: 94707 country: United States name: Alexa A Mazur, BA role: CONTACT phone: 610-724-1431 email: alexa@kintsugihealth.com name: Victoria Graham, MS role: CONTACT email: victoria@kintsugihealth.com name: Albert Ihochi, MBA role: PRINCIPAL_INVESTIGATOR name: Prentice Tom, MD role: SUB_INVESTIGATOR lat: 37.87159 lon: -122.27275 hasResults: False
nctId: NCT06374043 id: 2020/1002 briefTitle: Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. acronym: @HOME overallStatus: COMPLETED date: 2021-05-11 date: 2022-09-13 date: 2022-09-13 date: 2024-04-18 date: 2024-04-22 name: University Medical Center Groningen class: OTHER name: AstraZeneca briefSummary: Randomized placebo-controlled double-blind cross-over N=1 trial in adult male and female patients with UACR \>20 mg/g (2.26 mg/mmol) with type 2 diabetes treated in primary or secondary healthcare.
Participants will be randomly assigned to a cross-over study consisting of two periods of 1-week treatment with dapagliflozin 10 mg/day and two periods of 1-week treatment with placebo in random order with a 1-week wash-out period between every treatment period to avoid cross-over effects. conditions: Diabetes Mellitus, Type 2 conditions: Diabetes Mellitus Type 2 With Proteinuria conditions: Diabetes Mellitus conditions: Diabetes conditions: Diabetes Complications conditions: Albuminuria conditions: Chronic Kidney Diseases conditions: Chronic Kidney Disease Due to Type 2 Diabetes Mellitus conditions: CKD conditions: Proteinuria studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomized placebo-controlled double-blind cross-over trial with repeated administration (i.e., a series of N=1 trials). primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 20 type: ACTUAL name: Dapagliflozin 10mg Tab name: Placebo name: Withings BPM Connect name: Withings Body+ name: Hem-Col Capillary Blood Collection Device name: MEMS (Medication Electronic Monitoring System) Cap name: Questionnaire: participants' perspectives toward remote data collection measure: UACR response measure: Systolic blood pressure response measure: Body weight response measure: eGFR response measure: Fasting plasma glucose response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ziekenhuisgroep Twente city: Almelo country: Netherlands lat: 52.35667 lon: 6.6625 facility: University Medical Center Groningen city: Groningen country: Netherlands lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06374030 id: EDSAM2024 briefTitle: Retrospective Study of Airway Management in Dutch ED's overallStatus: ACTIVE_NOT_RECRUITING date: 2019-01-01 date: 2023-12-31 date: 2024-12-31 date: 2024-04-18 date: 2024-04-18 name: Medical Centre Leeuwarden class: OTHER name: VieCuri Medical Centre name: Catharina Ziekenhuis Eindhoven name: Rijnstate Hospital name: Zuyderland Medical Centre briefSummary: Describing characteristics of the practice of airway management in Dutch emergency departments, including information about patient demographics, indications, performer characteristics, equipment and medication used and complications due to intubation. conditions: Endotracheal Intubation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: Endotracheal intubation measure: Different complications of endotracheal intubation measure: Intubator characteristics measure: Indication for intubation measure: Sedation agent used measure: Paralytic agent used measure: Sedative agent after intubation measure: Method of intubation measure: Patient characteristics sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Leeuwarden Medical Centre city: Leeuwarden zip: 8934AD country: Netherlands lat: 53.20139 lon: 5.80859 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-12-15 uploadDate: 2024-03-20T05:01 filename: Prot_SAP_000.pdf size: 247439 hasResults: False
nctId: NCT06374017 id: N-258-2023 briefTitle: Evaluation of Lidocaine Spray Versus Dexmetomidine Spray on Stress Response overallStatus: RECRUITING date: 2023-09-20 date: 2024-04-30 date: 2024-05-10 date: 2024-04-18 date: 2024-04-18 name: Kasr El Aini Hospital class: OTHER briefSummary: Many studies discussed attenuating stress response by various measures but to the interest of our study , No one compared topical spray of both lidocaine and dexmedetomidine in attenuating the haemodynamic stress responses of laryngoscopy and endotracheal intubation, avoiding undesired systemic effects of drugs , conditions: To Measure Systolic Blood Pressure Postintubation studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: INVESTIGATOR count: 120 type: ESTIMATED name: Normal saline, Lidocaine, dexmetomidine measure: To measure systolic blood pressure immediately after intubation. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo University hospitals status: RECRUITING city: Cairo zip: 11559 country: Egypt name: Dina M Mohamed, MD role: CONTACT phone: 01005249134 phoneExt: MD email: Dinamahmoud@kasralainy.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False